Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease

Lancet

Volumn 354, Issue 9172, 1999, Pages 62-65

  Day, Richard ^a   Forbes, Alastair ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BASIC FIBROBLAST GROWTH FACTOR; CELL ADHESION MOLECULE; CHITOSAN; GROWTH FACTOR; HEPARIN; PROTEOHEPARAN SULFATE; SUCRALFATE; SYNDECAN; TUMOR NECROSIS FACTOR;

ANTICOAGULATION; CELL ADHESION; COST EFFECTIVENESS ANALYSIS; ENTERITIS; HUMAN; INTESTINE MUCOSA; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECTUM HEMORRHAGE; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE REPAIR;

EID: 0033519974     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)09267-8     Document Type: Note

References (37)

1. Gaffney P., O'Leary J., Doyle C.et al. Response to heparin in patients with ulcerative colitis. Lancet. 337:1991;238-239.
2. Gaffney P., Doyle Caffney A., Hogan J., Hayes D., Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol. 90:1995;220-223.
3. Evans R., Shim Wong V., Morris A., Rhodes J. Treatment of corticosteroid-resistant ulcerative colitis with heparin - a report of 16 cases. Alimen Pharmacol Ther. 1:1997;1037-1040.
4. Brazier F., Yzet T., Boruchowicz A., Colombel J., Duchmann J., Dupas J. Treatment of ulcerative colitis with heparin. Gastroenterology. 110:1996;872.
5. Folwaczny C., Fricke H., Endres S., Jochum M., Loeschke K. Anti-inflammatory properties of unfractionated heparin in patients with highly active ulcerative colitis: a pilot study. Am J Gastroenterol. 92:1997;911-912.
6. Dwarakanath A., Yu L., Brookes C., Pryce D., Rhodes J. "Sticky" neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut. 35:1995;585-588.
7. Brazier F., Yzet T., Cuchmann J., Iglicki F., Dupas J. Effect of heparin treatment on extraintestinal manifestations associated with inflammatory bowel diseases. Gastroenterology. 110:1996;872.
8. Zavgorodniy L., Mustgat A. Application of anticoagulants in the complex treatment of ulcerative colitis. Klin Med. 60:1982;74-80.
9. Kam A., Borda I., Inwood M., Thomson S. Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology. 68:1975;245-251.
10. Lindahl U., Höök M. Glycosaminoglycans and their binding to biological macromolecules. Ann Rev Biochem. 47:1978;385-417.
11. Tefferi A., Owen B., Nichols W., Witzig T., Owen W. Isolation of heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinoma. Blood. 74:1989;252-254.
12. Bobik A., Campbell J. Vascular derived growth factors - cell biology, pathophysiology and pharmacology. Pharmacol Rev. 45:1993;1-42.
13. Miller M., Krangel M. Biology and biochemistry of the chemokines - a family of chemotactic and inflammatory cytokines. Crit Rev Immunol. 12:1992;17-46.
14. Kjellén L., Lindahl U. Proteoglycans - structures and interactions. Annu Rev Biochem. 60:1991;443-445.
15. Redini F., Tixier J., Petitou M., Choay J., Robert L., Hornbech W. Inhibition of leukocyte elastase by heparin and its derivatives. Biochem J. 252:1988;515-519.
16. Bernfield M., Kokenyesi R., Kato M.et al. Biology of the syndecans: a family of transmembrane heparan sulphate proteglycans. Annu Rev Cell Biol. 8:1992;365-393.
17. Szabo S., Kusstatscgher G., Sakoulas G., Sandor Z., Vincze A., Jadus M. Growth factors: "endogenous drugs" for ulcer healing. Scand J Gastroenterol. 30(210):1995;15-18.
18. Klagsbrun M., Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell. 67:1991;229-231.
19. Yayon A., Klagsbrun M., Esko J., Leder P., Ornitz D. Cell surface, heparin-like molecules are required for binding basic fibroblast growth factor to its high affinity receptor. Cell. 64:1991;841-848.
20. Day R., Ilyas M., Daszak P., Talbot I., Forbes A. Expression of syndecan-1 in inflammatory bowel disease and a potential mechanism of heparin therapy. Gut. 41:1997;113. (no 3 ss).
21. Elenius K., Vainio S., Laato M., Salmivirta M., Thesleff I., Jalkanen M. Induced expression of syndecan in healing wounds. J Cell Biol. 14:1991;585-595.
22. Bousvaros A., Zurakowski D., Fishman S.et al. Serum basic fibroblast growth factor in pediatric Crohn's disease - implications for wound healing. Dig Dis Sci. 42:1997;378-386.
23. Ohtani H., Nakamura S., Watanabe Y., Mizoi T., Saku T., Nagura H. Immunocytochemical localization of basic fibroblast growth factor in carcinomas and inflammatory lesions of the human digestive tract. Lab Invest. 68:1993;520-527.
24. Wolfe M., Bynum T., Parsons W., Malone K., Szabo S., Folkman J. Safety and efficacy of an angiogenic peptide, basic fibroblast growth factor (bFGF), in the treatment of gastroduodenal ulcers. Gastroenterology. 106:1994;212.
25. Syngal S., Bynum T., Folkman J., Wolfe M. Randomized, double-blind, placebo-controlled trial of basic fibroblast growth-factor (bFGF) in the healing of gastroduodenal ulcers. Gastroenterology. 110:1996;267.
26. Kato M., Wang H., Kainulainen V.et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med. 4:1998;691-697.
27. Saksela O., Moscatelli D., Sommer A., Rifkin D. Endothelial cell-derived sulphate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol. 107:1988;743-751.
28. Ernst H., Müller M., Paulus A., Hahn E., Ell C. Immunohistochemical localization of basic fibroblast growth factor in the normal adult gastrointestinal tract. Eur J Gastroenterol Hepatol. 6:1994;559-564.
29. Murch S., MacDonald T., Walker-Smith J., Levin M., Lionetti P., Klein N. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet. 341:1993;14-71.
30. Kainulainen V., Nelimarkka L., Järveläinen H., Laato M., Jalkanen M., Elenius K. Suppression of syndecan-1 expression in endothelial cells by tumour necrosis factor-α J Biol Chem. 271:1996;18759-18766.
31. Kratz G., Arnander C., Swedenborg J.et al. Heparin-chitosan complexes stimulate wound healing in human skin. Scand J Plast Recons Hand Surg. 31:1997;19-23.
32. Folkman J., Sandor S., Stovroff M., McNeil P., Li W., Shing Y. Duodenal ulcer. Ann Surg. 214:1991;414-427.
33. Engelberg H. Orally ingested heparin is absorbed in humans. Clin Apple Thrombosis Hemostasis. 1:1995;283-285.
34. Gorrski A., Imiela J., Norsarzewski J. Oral heparin in the treatment of rheumatoid arthritis. J Immunol. 150:1991;239. (part 2).
35. Nelson R., Cecconi O., Roberts W., Aruffo A., Lindhardt R., Bevilacqua M. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood. 82:1993;3253-3258.
36. Sy M., Schneeberger E., McCluskey R., Greene M., Rosenberg R., Benacerraf B. Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cell Immunol. 82:1983;23-32.
37. Martz E., Benacerraf B. Inhibition of immune cell-mediated killing by heparin. Clin Immunol Immunopathol. 1:1973;533-546.